Pharmacy researcher developing nicotine vaccine, novel drug

November 17, 2015
Pharmacy researcher developing nicotine vaccine, novel drug
Xinyuan Chen, an assistant professor of biomedical and pharmaceutical sciences at URI’s College of Pharmacy, holds the patch he developed to deliver a powdered nicotine vaccine next to a traditional hypodermic needle.

A University of Rhode Island researcher in its College of Pharmacy is developing a nicotine vaccine and accompanying drug delivery system that he believes could lead to one of the most effective methods of combating cigarette smoking and other tobacco use.

Xinyuan Chen, an assistant professor of biomedical and pharmaceutical sciences, joined URI's College of Pharmacy after seven years at Massachusetts General Hospital in Boston, bringing with him a $1.08 million career development grant from the National Institute of Drug Abuse and a $432,000 grant from the National Institute of Allergy and Infectious Disease.

"My laboratory at URI is developing a laser-based delivery system for a powdered to improve nicotine vaccine effectiveness," Chen said. "There is no vaccine approved by the U.S. Food and Drug Administration for smoking."

Nicotine vaccines have been studied by other researchers, but none are in use yet.

Typical vaccines fight diseases, but Chen's vaccine and delivery system fight addictive behavior by blocking nicotine's entry into the brain.

"This will induce nicotine antibodies in the body," Chen said.

Described as "a laser-based epidermal (skin) powder delivery" system for improved nicotine vaccination, the laser treatment generates micro-channel arrays, or micro-pores in the skin, through which a powdered vaccine is delivered from a patch applied onto the skin.

Pharmacy researcher developing nicotine vaccine, novel drug
This is a close-up of Xinyuan Chen’s powdered nicotine vaccine and the patch used to deliver the medicine through micro-channel arrays made by a laser. Also in the photo is a traditional hypodermic syringe. The URI biomedical scientist believes the drug delivery system he is developing might someday eliminate the need for painful shots. Credit: Nora Lewis.

"Generally, vaccines are liquid, but powdered vaccines are more convenient and they have a longer shelf-life," Chen said.

One of the critical parts of the research involves adjuvants—ingredients added to vaccines to enhance effectiveness. Aluminum gels or salts are adjuvants used safely in a number of childhood and adult vaccines to improve their effectiveness. But some vaccine adjuvants can be toxic.

The adjuvants used in Chen's system, known as MPL and CpG are very powerful and can cause reactions.

"Normally, with a standard vaccine injection, all of the vaccine and all of the adjuvant are delivered all at once at the same location," Chen said. "This approach can be very difficult to handle by the skin and body overall."

Chen said epidermal powder delivery is a novel skin delivery technology capable of minimizing vaccine/adjuvant-induced skin reactions through the delivery of vaccine and powerful additives into hundreds or thousands of separated micro-channels surrounded by normal healthy skin. In other words, the vaccine and its additives are administered in small doses across many sites on the skin, resulting in less potent reactions.

In his lab, Chen displayed a small (6 by 6 millimeter) patch made of contact lens material and a small vial of powdered . That tiny patch, with 81 channels, can deliver 810 micrograms of medicine. The typical flu shot contains 45 micrograms of medicine.

The method also allows the incorporation of potent nano-encapsuated adjuvants to safely boost vaccination without significant local reactions.

"This system is expected to safely and profoundly boost nicotine antibody production and completely block nicotine entry into the brain," Chen said.

"We want to help those who are already addicted to , to help them quit smoking," the researcher added. "We also believe for other vaccines, that we could put multiple vaccines in one patch, thereby eliminating the need for multiple injections."

One of his goals is to eventually use the pain-free, needle-free system to eliminate the 30 to 40 needle injections babies receive in their early years.

Only on the job a few months at URI, Chen said he sees the University as a great place to build his research capacity.

"URI's strong College of Pharmacy allows me to pursue this novel vaccine , and I also see this as being an effective method for the delivery of other drugs."

Explore further: Nicotine vaccine prevents nicotine from reaching the brain

Related Stories

Nicotine vaccine prevents nicotine from reaching the brain

May 2, 2012
If smoking a cigarette no longer delivers pleasure, will smokers quit? It's the idea behind a nicotine vaccine being created by MIT and Harvard researchers, in which an injection of synthetic nanoparticles prompts the immune ...

Vaccination for nicotine addiction being developed

October 23, 2014
A Virginia Tech professor is working on a vaccine that could help smokers conquer their nicotine addiction, making many smoking-related diseases and deaths relics of the 21st century.

Scientists design nicotine vaccine that provokes robust immune response

January 12, 2015
When a promising nicotine vaccine failed in clinical trials a few years ago, scientists from The Scripps Research Institute (TSRI) were determined to keep trying to help smokers overcome their addiction.

Video: A new vaccine that could help you quit smoking

January 22, 2015
New research from the Journal of Medicinal Chemistry may help millions stick to a common resolution: quitting smoking.

Recommended for you

Tracing cell death pathway points to drug targets for brain damage, kidney injury, asthma

October 19, 2017
University of Pittsburgh scientists are unlocking the complexities of a recently discovered cell death process that plays a key role in health and disease, and new findings link their discovery to asthma, kidney injury and ...

Engineered protein treatment found to reduce obesity in mice, rats and primates

October 19, 2017
(Medical Xpress)—A team of researchers with pharmaceutical company Amgen Inc. report that an engineered version of a protein naturally found in the body caused test mice, rats and cynomolgus monkeys to lose weight. In their ...

Cancer drug found to offer promising results in treating sepsis in test mice

October 19, 2017
(Medical Xpress)—A combined team of researchers from China and the U.S. has found that a drug commonly used to treat lung cancer in humans offers a degree of protection against sepsis in test mice. In their paper published ...

New procedure enables cultivation of human brain sections in the petri dish

October 19, 2017
Researchers at the University of Tübingen have become the first to keep human brain tissue alive outside the body for several weeks. The researchers, headed by Dr. Niklas Schwarz, Dr. Henner Koch and Dr. Thomas Wuttke at ...

Inflammation trains the skin to heal faster

October 18, 2017
Scars may fade, but the skin remembers. New research from The Rockefeller University reveals that wounds or other harmful, inflammation-provoking experiences impart long-lasting memories to stem cells residing in the skin, ...

Large variety of microbial communities found to live along female reproductive tract

October 18, 2017
(Medical Xpress)—A large team of researchers from China (and one each from Norway and Denmark) has found that the female reproductive tract is host to a far richer microbial community than has been thought. In their paper ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.